UK Markets closed

Tiziana Life Sciences PLC (TLSA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.5100-0.0400 (-2.58%)
At close: 4:00PM EDT
1.5400 +0.03 (+1.99%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5500
Open1.5200
Bid1.4900 x 1100
Ask1.5400 x 800
Day's range1.4800 - 1.5400
52-week range1.3600 - 5.2900
Volume89,688
Avg. volume579,051
Market cap151.035M
Beta (5Y monthly)-0.10
PE ratio (TTM)N/A
EPS (TTM)-0.3100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Tiziana Life Sciences plc: PDMR Dealing

    LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 100,000 ordinary shares of 3p each in the market at a price of 52p per share. Th

  • Globe Newswire

    Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting

    LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- On 20 August 2021, Tiziana Life Sciences Plc (“Old Tiziana”) announced that it has formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd (“New Tiziana”), a Bermuda-incorporated company, as the ultimate parent company of the of the Tiziana Group, to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the “Scheme”). The board of directors of Old Tiziana (the “

  • Globe Newswire

    Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021

    Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet needLONDON, Sept. 24, 2021 (GLOBE NEWSWIRE) -- London, 24 September 2021 – Tiziana Life Sciences plc (“Tiziana”, LSE: TILS, NASDAQ: TLSA), a biotechnology company a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2021. Highlights during the period: CLINICA